Biotech Values

[dewophile]

i care because it not only translates to the bottom line for Q1 sales (i've had an ongoing dialogue regarding end user sales with jbog and others), it goes to managment's credibility. mnta stated they are at 40% and that there isn't an appreciable issue with uptake at hospital level vs retail. ii can accept some difference in share between the two, but not by a factor of 3x or 4x - that would mean mnta was clueless about their products uptake, or misleading, neither of which sits all that well with me

btw 70% share by volume makes the math even worse vs 60%